We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche’s Vision Loss Therapy to Compete With Regeneron’s Blockbuster
Roche’s Vision Loss Therapy to Compete With Regeneron’s Blockbuster
The FDA has approved Roche’s Vabysmo (faricimab-svoa) for treating the two most common forms of vision loss, paving the way for the drug to go head-to-head with Regeneron Pharmaceuticals’ blockbuster, Eylea (aflibercept).